Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics

M F Lorenzo-Gómez, B Padilla-Fernández, F J García-Criado, J A Mirón-Canelo, A Gil-Vicente, A Nieto-Huertos, J M Silva-Abuin, M F Lorenzo-Gómez, B Padilla-Fernández, F J García-Criado, J A Mirón-Canelo, A Gil-Vicente, A Nieto-Huertos, J M Silva-Abuin

Abstract

Introduction and hypothesis: Urinary tract infections (UTIs) are considered the most common bacterial infections, especially in women. The objective of this study was to evaluate the use of the sublingual bacterial vaccine Uromune® in order to prevent recurrent UTIs (RUTIs).

Methods: This study was conceived as a multicenter observational study. The clinical history of 319 women who presented at least 2 episodes of UTI in the last 6 months or 3 in 12 months was reviewed. Data related to treatment and clinical evolution were recorded and analyzed. A total of 159 patients received prophylactic treatment with Uromune® for a period of 3 months (group A) and 160 with sulfamethoxazole/trimethoprim 200/40 mg/day for a period of 6 months (group B). Uromune® contained an inactivated bacterial cell suspension of selected strains of Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris, and Enterococcus faecalis.

Results: Patients in group A experienced a highly significant reduction in the number of infections compared to patients in group B. In the first 3 months, the mean number of infections was 0.36 versus 1.60 (P < 0.0001), respectively. A significant reduction was also observed after 9 and 15 months (P < 0.0001). The numbers of patients who did not have any UTI at 3, 9, and 15 months were 101, 90, and 55 in group A versus 9, 4, and 0 in group B (P < 0.0001).

Conclusions: The results obtained in this study favor the use of this bacterial-based therapeutic vaccine as an effective strategy to reduce frequency, duration, severity, and costs of RUTIs.

Figures

Fig. 1
Fig. 1
Average of UTIs at the 3-, 9-, and 15-month evaluation time points. Error bars are ± 1 standard deviation
Fig. 2
Fig. 2
Average of UC+ at the 3-, 9-, and 15-month evaluation time points. Error bars are ± 1 standard deviation
Fig. 3
Fig. 3
Regression lines of the evolution in the number of UTIs and UC+ along the time of evaluation

References

    1. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;113(Suppl 1A):5S–13S. doi: 10.1016/S0002-9343(02)01054-9.
    1. Nicolle LE. Managing recurrent urinary tract infections in women. Womens Health (Lond Engl) 2005;1(1):39–50. doi: 10.2217/17455057.1.1.39.
    1. Naber KG, Cho YH, Matsumoto T, Schaeffer AJ. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int J Antimicrob Agents. 2009;33(2):111–119. doi: 10.1016/j.ijantimicag.2008.08.011.
    1. Cox CE, Lacy SS, Hinman F., Jr The urethra and its relationship to urinary tract infection. II. The urethral flora of the female with recurrent urinary infection. J Urol. 1968;99(5):632–638.
    1. Rahn DD. Urinary tract infections: contemporary management. Urol Nurs. 2008;28(5):333–341.
    1. Grabe M, Bjerklund-Johansen T, Botto H, Çek M, Naber K, Tenke P, et al. Guidelines on Urological Infections. Urology. Arnhem: EAU Guidelines Office; 2010.
    1. Mulholland SG. Controversies in management of urinary tract infection. Urology. 1986;27(2 Suppl):3–8.
    1. U.S. Census Bureau. U.S. interim projections by age, sex, race, and Hispanic origin (2008)
    1. Mayer TR. UTI in the elderly: how to select treatment. Geriatrics. 1980;35(3):67–77.
    1. Turck M, Stamm W. Nosocomial infection of the urinary tract. Am J Med. 1981;70(3):651–654. doi: 10.1016/0002-9343(81)90590-8.
    1. Nicolle LE, Ronald AR. Recurrent urinary tract infection in adult women: diagnosis and treatment. Infect Dis Clin North Am. 1987;1(4):793–806.
    1. Palou J, Pigrau C, Molina I, Ledesma JM, Angulo J, Grupo Colaborador Español del Estudio ARESC Etiology and sensitivity of uropathogens identified in uncomplicated lower urinary tract infections in women (ARESC Study): implications on empiric therapy (in Spanish) Med Clin (Barc) 2011;136(1):1–7. doi: 10.1016/j.medcli.2010.02.042.
    1. Carné X, Moreno V, Porta Serra M, Velilla E. Calculating the number of patients necessary for designing a clinical study (in Spanish) Med Clin (Barc) 1989;92(2):72–77.
    1. Andreu A, Planells I, Grupo Cooperativo Español para el Estudio de la Sensibilidad Antimicrobiana de los Patógenos Urinario Etiology of community-acquired lower urinary infections and antimicrobial resistance of Escherichia coli: a national surveillance study (in Spanish) Med Clin (Barc) 2008;130(13):481–486. doi: 10.1157/13119488.
    1. Pigrau-Serrallach C. Recurrent urinary tract infections (in Spanish) Enferm Infecc Microbiol Clin. 2005;23(Suppl 4):28–39. doi: 10.1157/13091446.
    1. McEwen LN, Farjo R, Foxman B. Antibiotic prescribing for cystitis: how well does it match published guidelines? Ann Epidemiol. 2003;13(6):479–483. doi: 10.1016/S1047-2797(03)00009-7.
    1. Glanz SA, Slinker BK. The first step: understanding simple linear regression. In: Glanz SA, Slinker BK, editors. Primer of applied regression and analysis of variance. New York: McGraw-Hill; 1990. pp. 27–35.
    1. Lettgen B. Prevention of recurrent urinary tract infections in female children: OM-89 immunotherapy compared with nitrofurantoin prophylaxis in a randomized pilot study. Curr Ther Res Clin Exp. 1996;57(6):464–475. doi: 10.1016/S0011-393X(96)80055-5.
    1. Bauer HW, Rahlfs VW, Lauener PA, Blessmann GS. Prevention of recurrent urinary tract infections with immuno-active E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies. Int J Antimicrob Agents. 2002;19(6):451–456. doi: 10.1016/S0924-8579(02)00106-1.
    1. Bauer HW, Alloussi S, Egger G, Blümlein HM, Cozma G, Schulman CC, Multicenter UTI Study Group A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur Urol. 2005;47(4):542–548. doi: 10.1016/j.eururo.2004.12.009.
    1. Nau GJ, Schlesinger A, Richmond JF, Young RA. Cumulative Toll-like receptor activation in human macrophages treated with whole bacteria. J Immunol. 2003;170(10):5203–5209.
    1. Sato S, Nomura F, Kawai T, Takeuchi O, Mühlradt PF, Takeda K, et al. Synergy and cross-tolerance between toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways. J Immunol. 2000;165(12):7096–7101.
    1. Underhill DM, Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol. 2002;14(1):103–110. doi: 10.1016/S0952-7915(01)00304-1.
    1. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med. 2005;11(4 Suppl):S45–S53. doi: 10.1038/nm1213.
    1. Eriksson K, Quiding-Järbrink M, Osek J, Möller A, Björk S, Holmgren J, et al. Specific-antibody-secreting cells in the rectums and genital tracts of nonhuman primates following vaccination. Infect Immun. 1998;66(12):5889–5896.
    1. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun. 1997;65(4):1387–1394.
    1. Quiding M, Nordström I, Kilander A, Andersson G, Hanson LA, Holmgren J, et al. Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory. J Clin Invest. 1991;88(1):143–148. doi: 10.1172/JCI115270.
    1. Cuburu N, Kweon MN, Song JH, Hervouet C, Luci C, Sun JB, et al. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine. 2007;25(51):8598–8610. doi: 10.1016/j.vaccine.2007.09.073.
    1. Negri DR, Riccomi A, Pinto D, Vendetti S, Rossi A, Cicconi R, et al. Persistence of mucosal and systemic immune responses following sublingual immunization. Vaccine. 2010;28(25):4175–4180. doi: 10.1016/j.vaccine.2010.04.013.
    1. Alecsandru D, Valor L, Sánchez-Ramón S, Gil J, Carbone J, Navarro J, et al. Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome. Clin Exp Immunol. 2011;164(1):100–107. doi: 10.1111/j.1365-2249.2011.04320.x.
    1. Johnson JR, Stamm WE. Urinary tract infections in women: diagnosis and treatment. Ann Intern Med. 1989;111(11):906–917.
    1. World Health Organization. WHO global strategy for containment of antimicrobial resistance (2001)
    1. European Medicines Agency. CVMP strategy on antimicrobials 2011-2015 (2011) EMA/CVMP/287420/2010
    1. Food and Drug Administration. Combating antibiotic resistance (2011)
    1. Centers for Disease Control and Prevention. Transatlantic Taskforce on Antimicrobial Resistance recommendations: recommendations for future collaboration between the U.S. and EU (2011)
    1. World Medical Association Declaration of Helsinki. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Note of clarification on paragraph 29 added by the WMA General Assembly, Washington 2002. Ethical principles for medical research involving human subjects

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever